Novartis CAR-T therapy leads to durable response in lymphoma study – Reuters
Reuters |
Novartis CAR–T therapy leads to durable response in lymphoma study
Reuters Kymriah belongs to an exciting new class of therapy called CAR-T. It works by harvesting a patient's own disease-fighting T–cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to circulate possibly for … Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete … #ASH17: How does Novartis' Kymriah DLBCL data stack up heading straight to a CAR–T showdown with Gilead? |
